Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be asked to login again with only ...

The utility of catalyst-free azide−alkyne [3 + 2] cycloaddition for the immobilization ... for the conjugation of ADIBO with a variety of molecules directly or via a PEG linker. You may have access to ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. That drug, Sirius’ lead ...

Swiss gene-editing specialist CRISPR Therapeutics (Nasdaq: CRSP) and San Diego, USA-based Sirius Therapeutics, which is developing innovative small interfering RNA (siRNA) therapies, announced a ...

CRISPR Therapeutics is looking to diversify its therapeutic toolbox, partnering with Sirius Therapeutics to co-develop an investigational siRNA therapeutic for thromboembolic disorders in a deal ...

Crispr will also be able to nominate up to two siRNA targets for research and development, for which it would retain opt-in rights to lead commercialization, the companies said. Sirius will be ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar partnership to develop small interfering RNA (siRNA) therapeutics across neuroscience, immunology and oncology. The collaboration ...

AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform. The partnership gives ...

The Vallabh/Minikel lab has received FDA clearance for the compound, a divalent short interfering RNA (siRNA) intended for delivery via intrathecal injection, as an Investigational New Drug for ...

The deal with ADARx expands AbbVie’s siRNA focus. Image credit: hapabapa / iStock Editorial via Getty Images. AbbVie has signed a collaboration and licensing agreement with US-based ADARx ...